Last reviewed 2026-04-19 · How we verify

GAd-209-FSP low dose

Nouscom SRL · Phase 1 active Biologic

GAd-209-FSP low dose is a Biologic drug developed by Nouscom SRL. It is currently in Phase 1 development.

At a glance

Generic name	GAd-209-FSP low dose
Sponsor	Nouscom SRL
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GAd-209-FSP low dose CI brief — competitive landscape report
GAd-209-FSP low dose updates RSS · CI watch RSS
Nouscom SRL portfolio CI

Frequently asked questions about GAd-209-FSP low dose

What is GAd-209-FSP low dose?

GAd-209-FSP low dose is a Biologic drug developed by Nouscom SRL.

Who makes GAd-209-FSP low dose?

GAd-209-FSP low dose is developed by Nouscom SRL (see full Nouscom SRL pipeline at /company/nouscom-srl).

What development phase is GAd-209-FSP low dose in?

GAd-209-FSP low dose is in Phase 1.

Manufacturer: Nouscom SRL — full pipeline
Compare: GAd-209-FSP low dose vs similar drugs
Pricing: GAd-209-FSP low dose cost, discount & access